TICKERNERD
Menu
ALGSALGSHealthcare · Biotechnology

ALGS Stock Forecast: Aligos Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$4.82
−2.82% on the day

The 8 Wall Street analysts covering Aligos Therapeutics, Inc. hold a median 12-month price target of $41 — +740.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 22 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$31.4M
Ticker Nerd rank
74/ 100
Median analyst target
$41
Analysts covering
8
Revenue$27.8M+2778.5% y/y
Operating income−$1.9M
Net income−$1.5M
Free cash flow−$25.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.6%
1M
−15.1%
YTD
−48.3%
1Y
−51.0%
From 52W high
−63.7%
From 52W low
+18.1%
$4
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALGS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aligos Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
74/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
86
Size
85
Issuance
70
Value
68
Growth
57
Quality
52
Accruals
42
Momentum
37
Volatility
18

Revisions (86): Analysts have, on balance, been raising their forecasts.

Volatility (18): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALGS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALGS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200Jan 26Apr 26Jul 26Oct 26ALGSHigh $175Median $41Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $20Median $41High $175

The green dot is the last close — the median target sits +740.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 May 2026Lake StreetInitiatesBuy—
28 May 2026Lake StreetInitiatesBuy$45
21 May 2026Cantor FitzgeraldInitiatesOverweight—
21 May 2026Cantor FitzgeraldInitiatesOverweight$20
26 Mar 2026WestPark CapitalInitiatesBuy—
19 Mar 2026JefferiesAssumesBuy$60 → $48
11 Mar 2026HC Wainwright & Co.ReiteratesBuy—
7 Jan 2026UBSInitiatesBuy—
12 Sept 2025HC Wainwright & Co.ReiteratesBuy—
18 Aug 2025HC Wainwright & Co.AssumesBuy$50
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
11 Mar 2025HC Wainwright & Co.MaintainsBuy—
7 Nov 2024HC Wainwright & Co.ReiteratesBuy—
23 Oct 2024HC Wainwright & Co.ReiteratesBuy—
20 Sept 2024HC Wainwright & Co.ReiteratesBuy—
19 Aug 2024HC Wainwright & Co.InitiatesBuy—
17 Jan 2023Piper SandlerMaintainsOverweight—
6 Jan 2023JefferiesUpgradeBuy—
6 Jan 2023Piper SandlerUpgradeOverweight—
3 Nov 2022SVB LeerinkMaintainsMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ALGS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

ALGS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Aligos Therapeutics, Inc. returned −51.0% against +15.6% for the S&P 500, dividends included.

ALGS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26ALGSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALGS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
2
Fundamentals

Aligos Therapeutics, Inc. (ALGS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.1×

Cheaper than 86% of US stocks

Price / sales
1.0×

Cheaper than 68% of US stocks

Price / book
1.0×

Cheaper than 71% of US stocks

EV / EBITDA
−0.1×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
2778.5%

Higher than 99% of US stocks

Earnings growth (YoY)
2778.5%

Higher than 99% of US stocks

Gross margin
—
Operating margin
−6.8%

Higher than 26% of US stocks

Net margin
−241.0%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−113.6%

Higher than 12% of US stocks

Return on assets
−49.1%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aligos Therapeutics, Inc. (ALGS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aligos Therapeutics, Inc. has a market value of $31.4M and an enterprise value of $4.5M.

  • Revenue in the twelve months to 30 June 2026: $31.5M. The latest quarter grew 2778.5% year on year.

  • Net income over the same four quarters: −$76.0M, a −241.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−7.30.

  • Free cash flow in the twelve months to 30 June 2026: −$94.5M.

  • Shares outstanding: 6.2M.

  • Trailing P/E: −2.1×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Aligos Therapeutics, Inc. employs 82 people — $384K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Oct 2026

Data provided by Twelve Data

Peers

ALGS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALGSAligos Therapeutics, Inc.$31.4M74
BSEMBioStem Technologies, Inc.$29.6M62
ESLAEstrella Immunopharma, Inc.$30.6M29
RNAZTransCode Therapeutics, Inc.$29.0M21
MGXMetagenomi Therapeutics, Inc.$30.6M29
FLNAFilana Therapeutics, Inc.$31.6M63
CVMCEL-SCI Corp.$28.1M39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aligos Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALGS news & analysis

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

GlobeNewsWire · 5 Oct 2026positive

Aligos Therapeutics announced that five abstracts have been accepted for presentation at the American Association for the Study of Liver Disease's The Liver Meeting 2026, scheduled for November 5-9, 2026 in Denver, CO. The abstracts are available on the AASLD website.

Why it matters — The acceptance of five abstracts for a major liver-disease conference highlights the company's ongoing research activity in its liver and viral disease pipeline.

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

GlobeNewsWire · 2 Sept 2026neutral

Aligos Therapeutics announced that members of its management team will present at the Cantor Global Healthcare Conference. The clinical-stage biopharmaceutical company, focused on therapies for liver and viral diseases, made the announcement on September 2, 2026.

Why it matters — The presentation gives Aligos management a public platform to discuss the company's pipeline and progress with the investment community.

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

GlobeNewsWire · 12 Aug 2026positive

Aligos Therapeutics announced that the first participant has been dosed in the Phase 1 study of ALG-170675, an investigational antisense oligonucleotide being evaluated for functional cure of chronic hepatitis B virus infection. The study is being conducted in China by partner Amoytop, which holds rights in Greater China.

Why it matters — This milestone advances a potentially best-in-class HBV candidate in early clinical development and reflects progress under Aligos' partnership with Amoytop in China.

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

GlobeNewsWire · 30 July 2026neutral

Aligos Therapeutics announced it will report its second quarter 2026 financial results on Thursday, August 6, 2026, prior to the opening of U.S. financial markets.

Why it matters — Investors and analysts following ALGS will look to the August 6 report for updates on the company's financial standing and progress in its clinical pipeline for liver and viral diseases.

FAQ

Frequently asked questions about ALGS stock

What is the ALGS stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Aligos Therapeutics, Inc. have a median 12-month price target of $41, with estimates ranging from $20 to $175. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALGS stock a buy right now?

Of the 8 analysts covering Aligos Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aligos Therapeutics, Inc. 74 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALGS?

As at 22 Oct 2026, Aligos Therapeutics, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (86 of 100).

Will ALGS stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +740.2% from the last close, and Ticker Nerd's factor model ranks Aligos Therapeutics, Inc. 74 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALGS stock forecast for 2030?

No analyst covering Aligos Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALGS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $175 over the next 12 months.

How has ALGS stock performed over the past year?

Aligos Therapeutics, Inc. returned -51.0% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aligos Therapeutics, Inc. do?

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for liver diseases and viral infections.

What is the latest news on ALGS?

The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026". Aligos Therapeutics announced that five abstracts have been accepted for presentation at the American Association for the Study of Liver Disease's The Liver Meeting 2026, scheduled for November 5-9, 2026 in Denver, CO. The abstracts are available on the AASLD website.

Company

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for liver diseases and viral infections. The company’s current programs target chronic hepatitis B, metabolic dysfunction-associated steatohepatitis, and coronavirus-related infections, using small-molecule and oligonucleotide approaches. Its pipeline includes investigational candidates designed to address unmet medical needs in these disease areas, with emphasis on antiviral activity and liver-disease biology. Aligos Therapeutics also works through research collaborations and licensing arrangements that support development of selected programs. Based in South San Francisco, California, Aligos Therapeutics operates within the biotechnology sector as a drug-development company centered on advancing therapies from discovery through clinical evaluation.

CEO Dr. Lawrence M. Blatt MBA, Ph.D. · 82 employees · United States · https://www.aligos.com